Amoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug

MT Newswires Live

Sep 23, 2024

Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.

Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.

The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.

Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2469159969"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2469159969\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2469159969?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-23 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469159969","market":"sh","top_or_hot":-1,"title":"Amoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug","media":"MT Newswires Live","content":"<html><body><p> Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.</p><p>Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.</p><p>The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.</p><p>Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-23 13:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.</p><p>Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.</p><p>The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.</p><p>Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688278","symbol_name":"特宝生物","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2469159969","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469159969","pubTimestamp":1727068886,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Xiamen Amoytop Biotech  obtained the exclusive rights for Tengji  Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.Price : 60.37, Change: -0.51, Percent Change: -0.84%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688278":"特宝生物","BK0239":"医药制造"},"translate_title":"淘拓生物获得腾基生物肝脏药物独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688278":0.9},"content_text":"Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}